Brief: Vigil Neuroscience Announces Interim Data From Phase 1 Trial Evaluating Vg-3927

Vigil Neuroscience

24/07/2024 13:16

July 24 (Reuters) - Vigil Neuroscience Inc  VIGL.O :
    * VIGIL NEUROSCIENCE ANNOUNCES INTERIM DATA FROM ITS ONGOING
PHASE
1 CLINICAL TRIAL EVALUATING VG-3927 IN HEALTHY VOLUNTEERS
SUPPORTING CONTINUED DEVELOPMENT IN ALZHEIMER’S DISEASE
    * VIGIL NEUROSCIENCE INC - VG-3927 ACHIEVED ROBUST DECREASE
OF
STREM2 IN CSF DEMONSTRATING CLINICAL PROOF-OF-TARGET ENGAGEMENT
    * VIGIL NEUROSCIENCE INC - COMPANY PLANS TO REPORT COMPLETE
PHASE
1 DATA, INCLUDING DATA FROM AD COHORT, IN Q1'2025
    * VIGIL NEUROSCIENCE INC - VG-3927 SHOWS FUNCTIONAL AND
DURABLE
TARGET ENGAGEMENT
    * VIGIL NEUROSCIENCE- PHARMACOKINETIC AND PHARMACODYNAMIC
PROFILE
OF VG-3927 SUPPORTS CONTINUED DEVELOPMENT AS POTENTIAL
ONCE-DAILY ORAL THERAPY FOR AD

Source text for Eikon:  ID:nGNX7R9wSC 
Further company coverage:  VIGL.O 

 ((Reuters.Briefs@thomsonreuters.com;))